Eagle Pharmaceuticals Inc (OQ:EGRX)

Business Focus: Specialty & Advanced Pharmaceuticals

Apr 15, 2024 07:00 am ET

Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcomi

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that data from the Company’s Phase III trial demonstrating the sustained response of amisulpride for the rescue treatment of postoperative nausea and vomiting...

Apr 12, 2024 04:05 pm ET

Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the “Company”) today announced that it received a notice (the “Notice”) on April 8, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that due...

Feb 11, 2024 04:32 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Eagle Pharmaceuticals, Inc. - EGRX

Pomerantz LLP announces that a class action lawsuit has been filed against Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or...

Feb 09, 2024 12:15 pm ET

Shareholders of Eagle Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before February 9, 2024 to Discuss Your Rights - EGRX

NEW YORK, NY / ACCESSWIRE / February 9, 2024 / If you suffered a loss on your Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:

Feb 09, 2024 11:30 am ET

Levi & Korsinsky Reminds Eagle Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 9, 2024 - EGRX

Feb 09, 2024 11:00 am ET

EAGLE PHARMACEUTICALS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him

If you suffered losses exceeding $100,000 investing in Eagle Pharmaceuticals stock or options between August 8, 2023 and November 28, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/EGRX.

Feb 09, 2024 07:30 am ET

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 9, 2024 in Eagle Pharmaceuticals, Inc. Lawsuit - EGRX

Feb 09, 2024 05:20 am ET

Shareholders of Eagle Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before February 9, 2024 to Discuss Your Rights - EGRX

Feb 09, 2024 05:00 am ET

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / February 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ:EGRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Feb 09, 2024 04:45 am ET

Eagle Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before February 9, 2024 to Discuss Your Rights - EGRX

NEW YORK, Feb. 9, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Eagle Pharmaceuticals, Inc..

Feb 08, 2024 06:30 pm ET

Shareholders that lost money on Eagle Pharmaceuticals, Inc. (EGRX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

NEW YORK, NY / ACCESSWIRE / February 8, 2024 / If you suffered a loss on your Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:

Feb 08, 2024 06:20 pm ET

EGRX DEADLINE TOMORROW: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Eagle Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important February 9 Deadline in Securities Class Act

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) between August 8, 2023 and November 28, 2023, both dates inclusive (the “Class Period”), of the important...

Feb 08, 2024 04:30 pm ET

Class Action Filed Against Eagle Pharmaceuticals, Inc. (EGRX) - February 9, 2024 Deadline to Join - Contact Levi & Korsinsky

Feb 08, 2024 03:15 pm ET

EGRX Investors Have Opportunity to Lead Eagle Pharmaceuticals, Inc. Securities Fraud Lawsuit

LOS ANGELES, Feb. 8, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company") (NASDAQ: EGRX).

Feb 08, 2024 03:00 pm ET

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Eagle Pharmaceuticals, Inc. (EGRX)

The Law Offices of Frank R. Cruz reminds investors of the upcoming February 9, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Eagle Pharmaceuticals, Inc. (“Eagle Pharmaceuticals” or the “Company”) (NASDAQ:

Feb 08, 2024 12:48 pm ET

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc.(EGRX) Investors of a Class Action Lawsuit and Upcoming Deadline

Levi & Korsinsky, LLP notifies investors in Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company") (NASDAQ: EGRX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Eagle...

Feb 08, 2024 11:00 am ET

EAGLE PHARMACEUTICALS 48 HOUR DEADLINE ALERT: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Eagle Pharmaceuticals, Inc. (“Eagle Pharmaceuticals” or the “Company”) (NASDAQ: EGRX) and reminds investors of the February 9, 2024 deadline to...

Feb 08, 2024 09:52 am ET

EGRX FINAL DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Eagle Pharmaceuticals (EGRX) Investors with Substantial Losses to Contact Firm Before Feb. 9th Deadline in Securities Fra

Hagens Berman urges Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) investors who suffered substantial losses to submit your losses now. Class Period: Aug. 8, 2023 – Nov. 28, 2023Lead Plaintiff Deadline: Feb. 9, 2024Visit:...

Feb 08, 2024 04:45 am ET

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Eagle Pharmaceuticals Investors of a Lead Plaintiff Deadline of February 9, 2024

NEW YORK, Feb. 8, 2024 /PRNewswire/ -- Attention Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals") (NASDAQ: EGRX) shareholders:

Feb 08, 2024 04:00 am ET

FINAL DEADLINE FRIDAY: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / February 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ:EGRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Feb 07, 2024 02:20 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Eagle Pharmaceuticals, Inc. - EGRX

NEW YORK, Feb. 7, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ: EGRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

Feb 07, 2024 12:00 pm ET

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Eagle Pharmaceuticals, Inc. (EGRX)

Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming February 9, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Eagle Pharmaceuticals, Inc. (“Eagle...

Feb 07, 2024 08:00 am ET

3-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / February 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ:EGRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Feb 06, 2024 01:15 pm ET

EGRX Investors Have Opportunity to Lead Eagle Pharmaceuticals, Inc. Securities Fraud Lawsuit

LOS ANGELES, Feb. 6, 2024 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company") (NASDAQ: EGRX).

Feb 06, 2024 04:45 am ET

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc.(EGRX) Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, Feb. 6, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company") (NASDAQ: EGRX) of a class action securities lawsuit.

Feb 06, 2024 04:00 am ET

FEBRUARY 9 DEADLINE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / February 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ:EGRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Feb 05, 2024 12:52 pm ET

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc.(EGRX) Investors of a Class Action Lawsuit and Upcoming Deadline

Feb 05, 2024 12:06 pm ET

DEADLINE ALERT for GM, EGRX, MRCY, and ON: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....

Feb 05, 2024 12:00 pm ET

DEADLINE ALERT for EGRX, ON, MRCY, LOVE: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....

Feb 05, 2024 09:55 am ET

Eagle Pharmaceuticals (EGRX) Tells SEC It Improperly Accounted for Past Two Quarters and Defaults on Lender Agreement - Hagens Berman

Feb 05, 2024 08:00 am ET

5-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / February 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ: EGRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Feb 05, 2024 08:00 am ET

Holzer & Holzer, LLC Reminds Investors of February 9, 2024 Lead Plaintiff Deadline in Eagle Pharmaceuticals, Inc. (EGRX) Class Action Lawsuit – Nationally Ranked Investors’ Rights Firm Holzer & Holzer

Holzer & Holzer, LLC reminds investors that a shareholder class action lawsuit has been filed against Eagle Pharmaceuticals, Inc. (“Eagle Pharmaceuticals” or the “Company”) (NASDAQ: EGRX). The lawsuit alleges Eagle Pharmaceuticals made false or...

Feb 04, 2024 09:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Eagle Pharmaceuticals, Golden Heaven, Inspire Medical, and Driven and Encourages Investors to Contact t

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX), Golden Heaven Group Holdings Ltd....

Feb 04, 2024 01:08 pm ET

ROSEN, NATIONAL TRIAL COUNSEL, Encourages Eagle Pharmaceuticals, Inc. Investors to Secure Counsel Before Important February 9 Deadline in Securities Class Action – EGRX

Feb 03, 2024 12:40 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Eagle Pharmaceuticals, Inc. - EGRX

Feb 03, 2024 09:30 am ET

ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Eagle Pharmaceuticals, Inc. Investors to Secure Counsel Before Important February 9 Deadline in Securities Class Action - EGRX

NEW YORK, Feb. 3, 2024 /PRNewswire/ --

Feb 03, 2024 07:00 am ET

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / February 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ: EGRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Feb 02, 2024 08:45 am ET

EAGLE PHARMACEUTICALS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him

Feb 02, 2024 08:00 am ET

SHAREHOLDER ACTION DEADLINE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / February 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ:EGRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Feb 02, 2024 04:45 am ET

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 9, 2024 - (NASDAQ: EGRX)

NEW YORK, Feb. 2, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Eagle Pharmaceuticals, Inc..

Feb 01, 2024 08:13 pm ET

ROSEN, A LEADING LAW FIRM, Encourages Eagle Pharmaceuticals, Inc. Investors to Secure Counsel Before Important February 9 Deadline in Securities Class Action – EGRX

Feb 01, 2024 05:30 pm ET

EAGLE PHARMACEUTICALS INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceutic

Feb 01, 2024 04:05 pm ET

Eagle Pharmaceuticals (EGRX) Tells SEC It Improperly Accounted for Past Two Quarters and Defaults on Lender Agreement - Hagens Berman

Feb 01, 2024 12:57 pm ET

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc.(EGRX) Investors of a Class Action Lawsuit and Upcoming Deadline

Feb 01, 2024 12:00 pm ET

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Eagle Pharmaceuticals, Inc. (EGRX)

Feb 01, 2024 07:00 am ET

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / February 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ:EGRX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Feb 01, 2024 04:45 am ET

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Eagle Pharmaceuticals Investors of a Lead Plaintiff Deadline of February 9, 2024

NEW YORK, Feb. 1, 2024 /PRNewswire/ -- Attention Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals") (NASDAQ: EGRX) shareholders:

Jan 31, 2024 09:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Microvast, Eagle Pharmaceuticals, Golden Heaven, and Inspire Medical and Encourages Investors to Contac

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Microvast Holdings, Inc. (NASDAQ: MVST), Eagle Pharmaceuticals, Inc. (NASDAQ:...

Jan 31, 2024 12:07 pm ET

DEADLINE ALERT for GM, EGRX, MRCY, and ON: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Jan 31, 2024 08:00 am ET

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / January 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ:EGRX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Jan 30, 2024 02:53 pm ET

EGRX Investors Have Opportunity to Lead Eagle Pharmaceuticals, Inc. Securities Fraud Lawsuit

BENSALEM, Pa., Jan. 30, 2024 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company") (NASDAQ: EGRX).

Jan 30, 2024 08:00 am ET

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / January 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ:EGRX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Jan 30, 2024 04:45 am ET

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc. (EGRX) Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, Jan. 30, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company") (NASDAQ: EGRX) of a class action securities lawsuit.

Jan 29, 2024 01:01 pm ET

EGRX 11-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Eagle Pharmaceuticals (EGRX) Investors with Substantial Losses to Contact Firm Before Feb. 9th Deadline in Securities Fr

Jan 29, 2024 12:30 pm ET

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc. (EGRX) Investors of a Class Action Lawsuit and Upcoming Deadline

Jan 29, 2024 10:00 am ET

DEADLINE ALERT for EGRX, ON, MRCY, LOVE: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Jan 28, 2024 10:15 pm ET

EARLY FEBRUARY DEADLINE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / January 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ:EGRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Jan 27, 2024 09:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Microvast, Eagle Pharmaceuticals, Golden Heaven, and Inspire Medical and Encourages Investors to Contac

Jan 27, 2024 07:55 pm ET

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Eagle Pharmaceuticals, Inc. Investors to Secure Counsel Before Important February 9 Deadline in Securities Class Action – EGRX

Jan 27, 2024 07:00 am ET

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / January 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ: EGRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Jan 26, 2024 02:50 pm ET

ROSEN, A LEADING LAW FIRM, Encourages Eagle Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - EGRX

NEW YORK, Jan. 26, 2024 /PRNewswire/ --

Jan 26, 2024 12:33 pm ET

EGRX STOCKHOLDERS: Robbins LLP Reminds Eagle Pharmaceuticals Shareholders of Pending Lead Plaintiff Deadline – February 9, 2024

Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) securities between August 8, 2023 and November 28, 2023....

Jan 26, 2024 12:00 pm ET

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Eagle Pharmaceuticals, Inc. (EGRX)

Jan 26, 2024 10:26 am ET

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Eagle Pharmaceuticals, Inc. - EGRX

Jan 26, 2024 09:12 am ET

Eagle Pharmaceuticals’ (EGRX) Line of Credit Reduced Amid Pending Restatement and Securities Fraud Class Action - Hagens Berman

Jan 26, 2024 08:00 am ET

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / January 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ:EGRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Jan 26, 2024 04:45 am ET

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 9, 2024 - (NASDAQ: EGRX)

NEW YORK, Jan. 26, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Eagle Pharmaceuticals, Inc..

Jan 25, 2024 12:55 pm ET

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc. (EGRX) Investors of a Class Action Lawsuit and Upcoming Deadline

Jan 25, 2024 09:15 am ET

EAGLE PHARMACEUTICALS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact H

Jan 25, 2024 09:00 am ET

EGRX Investors Have Opportunity to Lead Eagle Pharmaceuticals, Inc. Securities Fraud Lawsuit

LOS ANGELES, Jan. 25, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company") (NASDAQ: EGRX).

Jan 25, 2024 04:45 am ET

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Eagle Pharmaceuticals Investors of a Lead Plaintiff Deadline of February 9, 2024

NEW YORK, Jan. 25, 2024 /PRNewswire/ -- Attention Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals") (NASDAQ: EGRX) shareholders:

Jan 25, 2024 12:00 am ET

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / January 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ:EGRX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Jan 24, 2024 12:07 pm ET

DEADLINE ALERT for GM, EGRX, MRCY, and ON: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Jan 24, 2024 09:45 am ET

EAGLE PHARMACEUTICALS SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Cont

Jan 24, 2024 07:00 am ET

INVESTOR DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / January 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ:EGRX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Jan 23, 2024 09:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fisker, Microvast, Eagle Pharmaceuticals, and Golden Heaven and Encourages Investors to Contact the Fir

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Fisker Inc. (NYSE: FSR), Microvast Holdings, Inc. (NASDAQ: MVST), Eagle...

Jan 23, 2024 04:02 pm ET

EGRX Investors Have Opportunity to Lead Eagle Pharmaceuticals, Inc. Securities Fraud Lawsuit

LOS ANGELES, Jan. 23, 2024 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company") (NASDAQ: EGRX).

Jan 23, 2024 05:00 am ET

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / January 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ:EGRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Jan 23, 2024 04:45 am ET

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc.(EGRX) Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, Jan. 23, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company") (NASDAQ: EGRX) of a class action securities lawsuit.

Jan 22, 2024 05:59 pm ET

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Eagle Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – EGRX

Jan 22, 2024 04:03 pm ET

Eagle Pharmaceuticals’ (EGRX) Line of Credit Reduced Amid Pending Restatement and Securities Fraud Class Action - Hagens Berman

Jan 22, 2024 01:38 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Eagle Pharmaceuticals, Inc. - EGRX

NEW YORK, Jan. 22, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ: EGRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

Jan 22, 2024 12:53 pm ET

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc.(EGRX) Investors of a Class Action Lawsuit and Upcoming Deadline

Jan 22, 2024 07:00 am ET

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / January 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ: EGRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Jan 19, 2024 09:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fisker, Microvast, Eagle Pharmaceuticals, and Golden Heaven and Encourages Investors to Contact the Fir

Jan 19, 2024 03:37 pm ET

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Eagle Pharmaceuticals, Inc. (EGRX)

Jan 19, 2024 12:13 pm ET

Eagle Pharmaceuticals’ (EGRX) Line of Credit Reduced Amid Pending Restatement and Securities Fraud Class Action - Hagens Berman

Jan 19, 2024 04:45 am ET

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 9, 2024 - (NASDAQ: EGRX)

NEW YORK, Jan. 19, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Eagle Pharmaceuticals, Inc.

Jan 18, 2024 03:30 pm ET

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / January 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ:EGRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Jan 18, 2024 02:57 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Eagle Pharmaceuticals, Inc. - EGRX

Jan 18, 2024 01:06 pm ET

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc. (EGRX) Investors of a Class Action Lawsuit and Upcoming Deadline

Jan 18, 2024 12:05 pm ET

DEADLINE ALERT for GM, EGRX, MRCY, and ON: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Jan 18, 2024 12:00 pm ET

DEADLINE ALERT for EGRX, ON, MRCY, LOVE: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Jan 18, 2024 09:15 am ET

EAGLE PHARMACEUTICALS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact H

Jan 18, 2024 06:50 am ET

Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided an update on its bendamustine intellectual property portfolio. On January 16, 2024, the United States Court of Appeals for the Federal Circuit affirmed the...

Jan 18, 2024 04:45 am ET

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Eagle Pharmaceuticals Investors of a Lead Plaintiff Deadline of February 9, 2024

NEW YORK, Jan. 18, 2024 /PRNewswire/ -- Attention Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals") (NASDAQ: EGRX) shareholders:

Jan 17, 2024 09:45 am ET

EAGLE PHARMACEUTICALS SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To

Jan 16, 2024 05:46 pm ET

ROSEN, A RANKED AND LEADING FIRM, Encourages Eagle Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – EGRX

Jan 16, 2024 02:40 pm ET

EGRX Investors Have Opportunity to Lead Eagle Pharmaceuticals, Inc. Securities Fraud Lawsuit

BENSALEM, Pa., Jan. 16, 2024 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company") (NASDAQ: EGRX).

Jan 16, 2024 07:00 am ET

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / January 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ:EGRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Jan 16, 2024 04:45 am ET

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc.(EGRX) Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, Jan. 16, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company") (NASDAQ: EGRX) of a class action securities lawsuit.

Jan 15, 2024 09:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Veradigm, Fisker, Microvast, and Eagle Pharmaceuticals and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Veradigm Inc. (NASDAQ: MDRX), Fisker Inc. (NYSE: FSR), Microvast Holdings, Inc....

Jan 15, 2024 03:45 pm ET

EGRX INVESTOR ALERT: Hagens Berman, National Trial Attorneys, Encourages Eagle Pharmaceuticals (EGRX) Investors with Substantial Losses to Contact Firm, Securities Fraud Lawsuit Filed After Company Ad

Jan 15, 2024 12:36 pm ET

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc.(EGRX) Investors of a Class Action Lawsuit and Upcoming Deadline

Jan 14, 2024 10:15 pm ET

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / January 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ: EGRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Jan 14, 2024 10:15 am ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors in Eagle Pharmaceuticals, Inc. - EGRX

NEW YORK, Jan. 14, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ: EGRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

Jan 12, 2024 04:37 pm ET

ROSEN, A TOP RANKED LAW FIRM, Encourages Eagle Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – EGRX

Jan 12, 2024 12:00 pm ET

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Eagle Pharmaceuticals, Inc. (EGRX)

Jan 12, 2024 10:12 am ET

Eagle Pharmaceuticals (EGRX) Tells SEC It Improperly Accounted for Past Two Quarters and Defaults on Lender Agreement - Hagens Berman

Jan 12, 2024 07:00 am ET

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / January 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ:EGRX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Jan 12, 2024 04:45 am ET

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 9, 2024 - (NASDAQ: EGRX)

NEW YORK, Jan. 12, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Eagle Pharmaceuticals, Inc..

Jan 11, 2024 09:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Veradigm, Fisker, and Eagle Pharmaceuticals and Encourages Investors to Contact the Firm

Jan 11, 2024 01:03 pm ET

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc. (EGRX) Investors of a Class Action Lawsuit and Upcoming Deadline

Jan 11, 2024 11:00 am ET

EAGLE PHARMACEUTICALS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact H

Jan 11, 2024 10:00 am ET

EGRX Investors Have Opportunity to Lead Eagle Pharmaceuticals, Inc. Securities Fraud Lawsuit

LOS ANGELES, Jan. 11, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company") (NASDAQ: EGRX).

Jan 11, 2024 04:45 am ET

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Eagle Pharmaceuticals Investors of a Lead Plaintiff Deadline of February 9, 2024

NEW YORK, Jan. 11, 2024 /PRNewswire/ -- Attention Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals") (NASDAQ: EGRX) shareholders:

Jan 10, 2024 12:11 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors in Eagle Pharmaceuticals, Inc. - EGRX

Pomerantz LLP is investigating claims on behalf of investors of Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980....

Jan 10, 2024 12:08 pm ET

DEADLINE ALERT for GM, EGRX, MRCY, and ON: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Jan 10, 2024 10:00 am ET

EAGLE PHARMACEUTICALS SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Cont

Jan 09, 2024 10:45 pm ET

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / January 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ:EGRX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Jan 09, 2024 05:45 pm ET

ROSEN, LEADING INVESTOR COUNSEL, Encourages Eagle Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - EGRX

NEW YORK, Jan. 9, 2024 /PRNewswire/ --

Jan 09, 2024 03:21 pm ET

EGRX Investors Have Opportunity to Lead Eagle Pharmaceuticals, Inc. Securities Fraud Lawsuit

LOS ANGELES, Jan. 9, 2024 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company") (NASDAQ: EGRX).

Jan 09, 2024 01:12 pm ET

DEADLINE ALERT for EGRX, ON, MRCY, LOVE: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Jan 09, 2024 07:00 am ET

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses to Contact the Firm

Jan 09, 2024 04:45 am ET

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc.(EGRX) Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, Jan. 9, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company") (NASDAQ: EGRX) of a class action securities lawsuit.

Jan 08, 2024 06:31 pm ET

ROSEN, A RESPECTED AND LEADING FIRM, Encourages Eagle Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – EGRX

Jan 08, 2024 05:43 pm ET

Eagle Pharmaceuticals (EGRX) Tells SEC It Improperly Accounted for Past Two Quarters and Defaults on Lender Agreement - Hagens Berman

Jan 08, 2024 12:58 pm ET

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc. (EGRX) Investors of a Class Action Lawsuit and Upcoming Deadline

Jan 07, 2024 11:20 pm ET

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / January 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ:EGRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Jan 07, 2024 09:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Veradigm, Fisker, and Eagle Pharmaceuticals and Encourages Investors to Contact the Firm

Jan 06, 2024 10:00 am ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors in Eagle Pharmaceuticals, Inc. - EGRX

NEW YORK, Jan. 6, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ: EGRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

Jan 05, 2024 02:03 pm ET

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Eagle Pharmaceuticals (EGRX) Investors with Substantial Losses to Contact Firm, Securities Fraud Lawsuit Pending over Accounting Woes

Jan 05, 2024 12:06 pm ET

DEADLINE ALERT for GM, EGRX, MRCY, and ON: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Jan 05, 2024 09:45 am ET

EAGLE PHARMACEUTICALS SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceutical

Jan 05, 2024 12:00 am ET

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / January 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ:EGRX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Jan 04, 2024 04:25 pm ET

Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Eagle Pharmaceuticals, Inc. (EGRX) Investors and Encourages Investors to Contact the Firm Before February

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the District of New Jersey on behalf of those who acquired Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX)...

Jan 04, 2024 01:20 pm ET

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc.(EGRX) Investors of a Class Action Lawsuit and Upcoming Deadline

Jan 04, 2024 11:00 am ET

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Eagle Pharmaceuticals, Inc. (EGRX)

Jan 04, 2024 08:45 am ET

EAGLE PHARMACEUTICALS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact H

Jan 04, 2024 07:00 am ET

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / January 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ:EGRX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Jan 03, 2024 09:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Microvast, Eagle Pharmaceuticals, and Golden Heaven and Encourages Investors to Contact the Firm

Jan 03, 2024 01:58 pm ET

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 9, 2024 – (NASDAQ: EGRX)

The Gross Law Firm issues the following notice to shareholders of Eagle Pharmaceuticals, Inc.. Shareholders who purchased shares of EGRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff...

Jan 03, 2024 06:30 am ET

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / January 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ:EGRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Jan 02, 2024 06:00 pm ET

ROSEN, A LONGSTANDING LAW FIRM, Encourages Eagle Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - EGRX

NEW YORK, Jan. 2, 2024 /PRNewswire/ --

Jan 02, 2024 02:32 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors in Eagle Pharmaceuticals, Inc. - EGRX

Jan 02, 2024 11:00 am ET

EGRX Investors Have Opportunity to Lead Eagle Pharmaceuticals, Inc. Securities Fraud Lawsuit

BENSALEM, Pa., Jan. 2, 2024 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company") (NASDAQ: EGRX).

Jan 02, 2024 10:38 am ET

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Eagle Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – EGRX

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) between August 8, 2023 and November 28, 2023, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 9, 2024.

Jan 02, 2024 04:45 am ET

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc.(EGRX) Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, Jan. 2, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company") (NASDAQ: EGRX) of a class action securities lawsuit.

Jan 01, 2024 09:20 pm ET

SHAREHOLDER ACTION DEADLINE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / January 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ:EGRX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Jan 01, 2024 09:50 am ET

Eagle Pharmaceuticals (EGRX) Accounting Woes Continue Following Investor Fraud Suit - Hagens Berman

Dec 30, 2023 09:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Microvast, Eagle Pharmaceuticals, and Golden Heaven and Encourages Investors to Contact the Firm

Dec 30, 2023 11:00 am ET

Kaplan Fox & Kilsheimer LLP Reminds Eagle Pharmaceuticals Investors of a Class Action and Upcoming Deadline

Kaplan Fox & Kilsheimer LLP reminds investors that a complaint has been filed on behalf of investors that purchased or otherwise acquired Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX) securities between August 8, 2023 and...

Dec 29, 2023 02:57 pm ET

Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Eagle Pharmaceuticals, Inc. (EGRX) Investors and Encourages Investors to Contact the Firm Before February

Dec 29, 2023 02:21 pm ET

Eagle Pharmaceuticals (EGRX) Tells SEC It Improperly Accounted for Past Two Quarters and Defaults on Lender Agreement - Hagens Berman

Dec 29, 2023 08:00 am ET

Eagle Pharmaceuticals Shareholders Still Have Time to Participate in the EGRX Class Action; Contact Robbins LLP Today

Dec 29, 2023 07:00 am ET

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / December 29, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ:EGRX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Dec 28, 2023 05:46 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors in Eagle Pharmaceuticals, Inc. - EGRX

NEW YORK, Dec. 28, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ: EGRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

Dec 28, 2023 01:15 pm ET

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 9, 2024 – (NASDAQ: EGRX)

The Gross Law Firm issues the following notice to shareholders of Eagle Pharmaceuticals, Inc. Shareholders who purchased shares of EGRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff...

Dec 28, 2023 10:00 am ET

EGRX Investors Have Opportunity to Lead Eagle Pharmaceuticals, Inc. Securities Fraud Lawsuit

LOS ANGELES, Dec. 28, 2023 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company") (NASDAQ: EGRX).

Dec 28, 2023 08:00 am ET

EAGLE PHARMACEUTICALS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact H

Dec 27, 2023 11:55 pm ET

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / December 27, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ:EGRX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Dec 27, 2023 12:41 pm ET

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Eagle Pharmaceuticals, Inc. (EGRX)

Dec 27, 2023 12:06 pm ET

DEADLINE ALERT for GM, EGRX, MRCY, and ON: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Dec 27, 2023 09:30 am ET

EAGLE PHARMACEUTICALS SHAREHOLDER ALERT: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Conta

Dec 27, 2023 04:45 am ET

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc.(EGRX) Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, Dec. 27, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company") (NASDAQ: EGRX) of a class action securities lawsuit.

Dec 26, 2023 10:20 pm ET

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / December 26, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ:EGRX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Dec 26, 2023 09:00 pm ET

EAGLE PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Eagle Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Eagle Pharmaceuticals, Inc. (“Eagle Pharmaceuticals” or the “Company”) (NASDAQ: EGRX) in the...

Dec 26, 2023 08:45 pm ET

Robbins LLP Reminds Investors of Eagle Pharmaceuticals, Inc. that There is Still Time to Move for Lead Plaintiff in the EGRX Class Action

Dec 26, 2023 02:42 pm ET

EGRX Investors Have Opportunity to Lead Eagle Pharmaceuticals, Inc. Securities Fraud Lawsuit

LOS ANGELES, Dec. 26, 2023 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company") (NASDAQ: EGRX).

Dec 26, 2023 04:45 am ET

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc.(EGRX) Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, Dec. 26, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company") (NASDAQ: EGRX) of a class action securities lawsuit.

Dec 25, 2023 11:07 am ET

Eagle Pharmaceuticals (EGRX) Accounting Woes Continue Following Investor Fraud Suit - Hagens Berman

Dec 22, 2023 09:00 pm ET

EAGLE PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Eagle Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm

Dec 22, 2023 03:35 pm ET

Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Eagle Pharmaceuticals, Inc. (EGRX) Investors and Encourages Investors to Contact the Firm Before February

Dec 22, 2023 01:59 pm ET

Eagle Pharmaceuticals (EGRX) Tells SEC It Improperly Accounted for Past Two Quarters and Defaults on Lender Agreement - Hagens Berman

Dec 22, 2023 12:37 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Eagle Pharmaceuticals, Inc. - EGRX

Dec 21, 2023 01:53 pm ET

EGRX Alert: Kaplan Fox & Kilsheimer LLP Notifies Eagle Pharmaceuticals Investors of a Class Action and Highlights Upcoming Deadline

Dec 21, 2023 01:27 pm ET

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc. (EGRX) Investors of a Class Action Lawsuit and Upcoming Deadline

Dec 21, 2023 12:06 pm ET

DEADLINE ALERT for GM, EGRX, and MRCY: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Dec 21, 2023 08:00 am ET

EAGLE PHARMACEUTICALS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact H

Dec 21, 2023 07:00 am ET

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / December 21, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ:EGRX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Dec 20, 2023 01:02 pm ET

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 9, 2024 – (NASDAQ: EGRX)

Dec 19, 2023 11:55 pm ET

SHAREHOLDER ACTION DEADLINE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / December 19, 2023 / Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ:EGRX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Dec 19, 2023 09:11 pm ET

ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages Eagle Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – EGRX

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) resulting from allegations that Eagle Pharmaceuticals may have...

Dec 19, 2023 11:00 am ET

EGRX Investors Have Opportunity to Lead Eagle Pharmaceuticals, Inc. Securities Fraud Lawsuit

BENSALEM, Pa., Dec. 19, 2023 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company") (NASDAQ: EGRX).

Dec 19, 2023 09:30 am ET

EAGLE PHARMACEUTICALS ONGOING DEADLINE ALERT: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To

Dec 19, 2023 05:45 am ET

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / December 19, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ:EGRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Dec 19, 2023 04:45 am ET

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc.(EGRX) Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, Dec. 19, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company") (NASDAQ: EGRX) of a class action securities lawsuit.

Dec 18, 2023 06:32 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Eagle Pharmaceuticals, Inc. - EGRX

NEW YORK, Dec. 18, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ: EGRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

Dec 18, 2023 03:12 pm ET

EGRX Class Action Alert: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Eagle Pharmaceuticals, Inc. Class Action

Dec 18, 2023 02:31 pm ET

Eagle Pharmaceuticals (EGRX) Engaged in Accounting Fraud, Investor Suit Alleges - Hagens Berman

Dec 18, 2023 11:00 am ET

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Eagle Pharmaceuticals, Inc. (EGRX)

Dec 18, 2023 08:05 am ET

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc.(EGRX) Investors of a Class Action Lawsuit and Upcoming Deadline

Dec 18, 2023 04:45 am ET

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 9, 2024 - (NASDAQ: EGRX)

NEW YORK, Dec. 18, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Eagle Pharmaceuticals, Inc..

Dec 17, 2023 09:00 pm ET

EAGLE PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Eagle Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm

Dec 17, 2023 07:30 pm ET

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / December 17, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ:EGRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Dec 17, 2023 08:01 am ET

Kaplan Fox & Kilsheimer LLP Reminds Eagle Pharmaceuticals Investors of a Class Action and Upcoming Deadline

Dec 15, 2023 12:06 pm ET

DEADLINE ALERT for EH and EGRX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Dec 15, 2023 09:30 am ET

EAGLE PHARMACEUTICALS SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceutical

Dec 15, 2023 05:00 am ET

IMPORTANT DEADLINE ALERT: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses In Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / December 15, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ:EGRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Dec 14, 2023 02:18 pm ET

You are here

Eagle Pharmaceuticals Inc (OQ:EGRX)

Business Focus: Specialty & Advanced Pharmaceuticals